When supplements change the meaning of a blood test

Updated 10 Oct 2026

The exposure record belongs next to the result

My food log contains estimates rather than blood measurements. Vitamin D was explicitly not taken on the latest reported day, and biotin or creatine use has not been reported. The examples here explain why future supplement records should include actual products, doses and times; they do not establish an existing laboratory problem or a reason to order a large testing panel.

A supplement can change a result in more than one way. It can change the body process being measured, alter a marker without the implied disease, or interfere with the laboratory method itself. These are different explanations. Recognizing a possible interaction helps interpretation; it does not make every abnormal result harmless.

Biotin can affect the measuring method

Biotin is used in the chemistry of some immunoassays. A high circulating supplement exposure can disrupt that method, causing some results to read high and others low, depending on the assay. This is analytical interference: the number can change without the corresponding change in the hormone or disease being investigated. AACC laboratory guidance.

In a prospective study, 13 adults took 10 mg biotin daily for eight days. Their samples were tested using several platforms. On the Roche method, TSH measured two hours after the first dose was 34% lower; the TSH values still remained within the reference range in this sample. Other thyroid-related measurements also changed in a platform-dependent way. Ylli et al., 2021.

The experimental dose was 10,000 µg, so confusing milligrams and micrograms creates a thousand-fold error. That exposure should not be casually equated with ordinary food biotin. The study also does not prove that every contemporary test is affected: the exact assay, its design and the circulating exposure matter.

There is no universal washout interval

A separate study gave ten healthy adults 5 or 10 mg biotin daily for seven days and tested thyroid assays on three platforms. Interference appeared on Roche and Beckman methods, but not on the Abbott method in that protocol. With the 10 mg exposure, affected results could take roughly one or two days to return to baseline, depending on the platform. Zhang et al., 2020.

AACC guidance also explains that the required interval depends on dose, assay sensitivity and elimination, including slower elimination with impaired kidney function. It recommends communication with the laboratory and clinician rather than assuming a single interval works for every test. AACC recommendations.

The practical action is to disclose the product and follow the instructions for the planned test. A prescribed high-dose treatment should not be stopped merely because a general nutrition page mentions interference. If a result does not fit the clinical situation, the laboratory may be able to use a different method or request another sample under appropriate conditions.

The issue extends beyond thyroid testing

The FDA continues to describe reports of falsely low troponin results from biotin interference in certain assays, and maintains a list of affected devices. It also notes that some developers have addressed interference while others have not. This is a specific concern about a potentially misleading cardiac marker, not a claim that all troponin tests are unreliable. FDA assay information.

An emergency clinical assessment should not be delayed to complete a supplement washout. Disclosing the exposure lets the treating team interpret tests and choose methods in the actual situation.

Creatine presents a different interpretation problem

Creatine contributes to creatinine production, which can affect creatinine-based kidney estimates. This differs from biotin’s assay interference. Lugaresi et al., 2013.

That trial studied healthy men doing resistance training and eating at least 1.2 g/kg/day protein. Forty-six were randomized and 26 were analyzed after withdrawals and missed assessments. Creatine monohydrate was given as 20 g/day for five days, then 5 g/day, over 12 weeks. Kidney filtration measured with a separate tracer method did not show a significant group-by-time difference (P=.64), and measured urinary markers did not deteriorate. Serum creatinine itself was not significantly elevated in this trial. Original trial methods and results.

This provides reassurance within its tested population and duration. The small analyzed sample and substantial attrition limit what it establishes about rare effects, longer exposure, different products or people with existing kidney disease. “No demonstrated deterioration here” is more precise than “all kidney concerns are impossible.”

A second trial illustrates the statistical distinction

A 35-day trial randomized 36 healthy men to placebo, 3 g/day or 5 g/day creatine; 30 remained in the analysis after training-attendance exclusions. Within the creatine groups, creatinine increased and creatinine-based filtration estimates decreased, while the measured urinary injury markers did not change. However, the between-group comparisons were not significant. Vilar Neto et al., 2020.

That result should not be described as definitive evidence of a between-group creatinine increase. It does illustrate why the interpretation of a marker requires more than a direction of change, and why the study’s title alone is insufficient evidence for unrestricted safety. The absence of change in two injury markers over 35 days does not exclude every kind of kidney problem.

If creatine is later used, the clinician should know the formulation, dose and duration when interpreting kidney tests. That disclosure can inform whether another assessment is useful; it should not become a personal instruction to disregard a high creatinine result.

A small, useful record is enough

The practical supplement entry can contain:

• Product and formulation: the actual label, including combination products.
• Dose and unit: the amount taken, with mg, µg or IU kept distinct.
• Use: whether it was actually taken, when it started, and the last dose before a test.
• Test context: the laboratory’s instructions and any change agreed with the treating clinician.

This is a proposed recording format, not evidence that these products are in my routine. It also preserves an important distinction already needed for vitamin D: a plan to buy a supplement, ownership of it and a dose actually taken are different events.

The purpose is to make future numbers easier to interpret. Nutrition should improve the information available to clinical care, while the assay, symptom context and appropriate assessment still determine what a result means.

Back to investigations